Get the Stockscreener App
2.23
1.76%
-0.04
Rafael Holdings Inc stock is traded at $2.23, with a volume of 122.98K.
It is down -1.76% in the last 24 hours and up +25.28% over the past month.
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.
See More
Previous Close:
$2.27
Open:
$2.29
24h Volume:
122.98K
Relative Volume:
0.68
Market Cap:
$115.96M
Revenue:
$1.16M
Net Income/Loss:
$-32.23M
P/E Ratio:
-2.8408
EPS:
-0.785
Net Cash Flow:
$-27.90M
1W Performance:
-29.21%
1M Performance:
+25.28%
6M Performance:
+74.22%
1Y Performance:
+3.72%
1-Day Range:
$2.15
$2.362
1-Week Range:
$2.15
$3.24
52-Week Range:
$1.12
$3.96
Rafael Holdings Inc Stock (RFL) Company Profile
Name
Rafael Holdings Inc
Sector
Industry
Phone
212-658-1450
Address
520 BROAD STREET, NEWARK
Compare RFL vs CBRE, BEKE, JLL, CSGP, COMP
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RFL
Rafael Holdings Inc
|
2.23 | 115.96M | 1.16M | -32.23M | -27.90M | -0.785 |
CBRE
Cbre Group Inc
|
139.53 | 40.86B | 42.17B | 1.43B | 897.00M | 4.3837 |
BEKE
Ke Holdings Inc Adr
|
15.57 | 17.24B | 12.67B | 477.84M | 279.43M | 0.4156 |
JLL
Jones Lang Lasalle Inc
|
324.44 | 15.05B | 26.76B | 894.10M | 1.03B | 18.60 |
CSGP
Costar Group Inc
|
28.39 | 11.59B | 3.41B | 25.30M | 165.00M | 0.0602 |
COMP
Compass Inc
|
11.72 | 8.76B | 6.96B | -58.70M | 203.30M | -0.1082 |
Rafael Holdings Inc Stock (RFL) Latest News
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
EDGAR Filing Documents for 0001213900-26-076411 - SEC.gov
Rafael Holdings: Phase 3 LPLV complete; NDA submission and topline expected 2H 2026 - TradingView
Rafael Holdings (RFL) details late-stage Trappsol Cyclo program and 2026 NDA plans - Stock Titan
RFL Q1 2025 Earnings: Net Loss of $0.37 Per Share, Stock Declines 15%Profit Cycle Analysis - dars.gov.et
Innoviz appoints former Rafael defense CEO to board - Investing.com UK
Rafael Holdings Inc. (RFL) Q1 2025 Earnings: Wider-than-Expected Loss and Absent Revenue Trigger Sharp Share DeclineSpecial Dividend Alert - dars.gov.et
Lopez Holdings keeps investors in the dark on board slate as family war heats up - Bilyonaryo Business News
Dubai-based OSN Group proposes full ownership of Abu Dhabi-headquartered Anghami - MSN
OSN seeks full ownership of Anghami in proposed take-private deal - Wamda
ANGHAMI CONFIRMS RECEIPT OF PRELIMINARY, NON-BINDING GOING-PRIVATE PROPOSAL FROM CONTROLLING SHAREHOLDER, OSN STREAMING LIMITED; ANNOUNCES APPOINTMENT OF INDEPENDENT DIRECTORS AND FORMATION OF - Lelezard
Anghami Inc. Announces Board and Committee Change - marketscreener.com
ETFs Investing in Rafael Holdings, Inc. Class B Stocks - TradingView
Rafael Holdings: The Second Half Of Calendar 2026 Could Define This Company Forever - Seeking Alpha
Price to earnings forward of Rafael Holdings, Inc. – NYSE:RFL - TradingView
Enterprise value to EBITDA forward of Rafael Holdings, Inc. – NYSE:RFL - TradingView
Price to sales forward of Rafael Holdings, Inc. – NYSE:RFL - TradingView
Form 4 Rafael Holdings Inc Class B For: 23 June - Investing.com UK
Form 4 Rafael Holdings Inc Class B For: 23 June By Investing.com - Investing.com Canada
Tax withholding trims Rafael Holdings (NYSE: RFL) CFO share position - Stock Titan
Rafael Holdings Inc (RFL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Rafael Holdings Q1 2025 Earnings: Development Stage Loss of -$0.37; Shares Rise 3.8%Earnings Deceleration Risk - Město Břeclav
Rafael Holdings Inc (RFL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Rafael Holdings Inc (RFL) Valuation: PE, PB & Fair Value Analysis - TradingKey
Rafael Holdings Inc (RFL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Rafael Holdings Inc (RFL) Institutional Confidence - TradingKey
Rafael Holdings Inc (RFL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Rafael Holdings Inc (RFL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Rafael Holdings Inc (RFL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Rafael Holdings Inc (RFL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Rafael Holdings (RFL) CEO granted Class B shares with tax withholding update - Stock Titan
RFL Q1 2025 Earnings: Net Loss of $0.37 Per Share, Stock Rises 5.66%Earnings Beat Alert - newsline.com
RFL Q1 2025 Earnings: Loss Per Share of -$0.37 as Stock Rises 5.66%Net Income Trends - newsline.com
RFL Q1 2025 Earnings: Net Loss of $0.37 per Share as Holding Company Maintains Strategic FocusMargin Expansion Trends - newsline.com
Rafael Holdings Releases Q3 2026 Financial Results - AlphaStreet
Rafael Flat on Q3 Figures - TradingView
Rafael Holdings narrows Q3 loss to $(0.08) per share - scanx.trade
Rafael Holdings, Inc. 3Q 2026: Revenue $179K, EPS ($0.08) — 10-Q Summary - TradingView
RFL: Net loss widened to $20.5M on $630K revenue, with key clinical milestones expected in late 2026 - TradingView
Rafael Holdings (NYSE: RFL) posts Q3 2026 loss as it funds Trappsol Cyclo trial - Stock Titan
Rafael Holdings reports Q3 FY2026 net loss of $4.2M; cash $30.5M; NDA expected H2 2026 - TradingView
RFL: Pivotal Phase 3 trial completed; NDA submission and commercial transition expected in H2 2026 - TradingView
[8-K] Rafael Holdings, Inc. Reports Material Event - Stock Titan
Rafael Holdings Reports Third Quarter Fiscal 2026 Financial Results - The Manila Times
Rafael Holdings, Inc. Reports Q3 Fiscal 2026 Financial Results and Progress on Phase 3 TransportNPC™ Trial - Quiver Quantitative
BRIEF-Rafael Holdings Q3 Net Income USD -2.899 Million - TradingView
Rare disease trial milestone: Rafael plans 2026 NPC drug filing - Stock Titan
Rafael Holdings (RFL) completes Phase 3 TransportNPC trial - grafa.com
Rafael Holdings, Inc. Announces Completion Of Last Patient Last Visit For Pivotal Phase 3 TransportNPC Study Evaluating Trappsol Cyclo For The Treatment Of Niemann-Pick Disease Type C - marketscreener.com
Rafael Holdings Completes Pivotal Phase 3 TransportNPC Study - TipRanks
Rafael Holdings completes phase 3 NPC disease trial enrollment - Investing.com
Rafael Holdings Inc Stock (RFL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.47%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):